Share on LinkedInShare on LinkedIn

ARTICLE · 19 SEPTEMBER 2016

Pharma In Brief - Update On Recent PMPRB Litigation

The role and powers of the Patented Medicine Prices Review Board (the "PMPRB" or the "Board") are at issue in a number of recent proceedings.

CanadaFood, Drugs, Healthcare, Life Sciences

Cases:  Canada (Attorney General) v Sandoz Canada Inc. and Canada (Attorney General) v Ratiopharm Inc. (now Teva Canada Limited) (SCC: 36798)

Alexion Pharmaceuticals Inc. v Attorney General of Canada (Court File No. T-1537-15)

Alexion Pharmaceuticals Inc. v Attorney General of Canada (Court File No. T-1160-16)

Overview

The role and powers of the Patented Medicine Prices Review Board (the "PMPRB" or the "Board") are at issue in a number of recent proceedings. In particular, the Board's jurisdiction over generic products and the constitutionality of the excessive pricing provisions of the Patent Act have been raised. The PMPRB's excessive pricing guidelines have also been a topic of debate.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from